Amgen Q1: international sales and price rises to fill in for falls in Epogen, Aranesp
This article was originally published in Scrip
Executive Summary
Amgen reported higher sales volumes in the first quarter of 2012 for almost all of its marketed products on 24 April with the notable exceptions of Epogen (epoetin alfa) and Aranesp (darbepoetin alfa), for which sales dropped due to label changes for the biologics.